Comments on: Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations

Comments on: Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations https://www.novumpr.nl/2019/03/12/vertex-receives-approval-for-symdeko-tezacaftor-ivacaftor-and-ivacaftor-in-australia-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-aged-12-and-older-with-certain-cftr-gene-mutati/?utm_source=rss&utm_medium=rss&utm_campaign=vertex-receives-approval-for-symdeko-tezacaftor-ivacaftor-and-ivacaftor-in-australia-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-aged-12-and-older-with-certain-cftr-gene-mutati NovumPR press releases Tue, 12 Mar 2019 09:07:00 +0000 hourly 1 https://wordpress.org/?v=6.8.3